ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer (Englisch)
Freier Zugriff
- Neue Suche nach: Crabb, Simon J.
- Neue Suche nach: Birtle, Alison J.
- Neue Suche nach: Martin, Karen
- Neue Suche nach: Downs, Nichola
- Neue Suche nach: Ratcliffe, Ian
- Neue Suche nach: Maishman, Tom
- Neue Suche nach: Ellis, Mary
- Neue Suche nach: Griffiths, Gareth
- Neue Suche nach: Thompson, Stuart
- Neue Suche nach: Ksiazek, Lidia
- Neue Suche nach: Khoo, Vincent
- Neue Suche nach: Jones, Robert J.
- Neue Suche nach: Crabb, Simon J.
- Neue Suche nach: Birtle, Alison J.
- Neue Suche nach: Martin, Karen
- Neue Suche nach: Downs, Nichola
- Neue Suche nach: Ratcliffe, Ian
- Neue Suche nach: Maishman, Tom
- Neue Suche nach: Ellis, Mary
- Neue Suche nach: Griffiths, Gareth
- Neue Suche nach: Thompson, Stuart
- Neue Suche nach: Ksiazek, Lidia
- Neue Suche nach: Khoo, Vincent
- Neue Suche nach: Jones, Robert J.
In:
Investigational New Drugs
;
35
, 5
; 599-607
;
2017
-
ISSN:
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
-
Beteiligte:Crabb, Simon J. ( Autor:in ) / Birtle, Alison J. ( Autor:in ) / Martin, Karen ( Autor:in ) / Downs, Nichola ( Autor:in ) / Ratcliffe, Ian ( Autor:in ) / Maishman, Tom ( Autor:in ) / Ellis, Mary ( Autor:in ) / Griffiths, Gareth ( Autor:in ) / Thompson, Stuart ( Autor:in ) / Ksiazek, Lidia ( Autor:in )
-
Erschienen in:Investigational New Drugs ; 35, 5 ; 599-607
-
Verlag:
- Neue Suche nach: Springer US
- Neue Suche nach: Springer Science + Business Media B.V
-
Erscheinungsort:Dordrecht [u.a.]
-
Erscheinungsdatum:2017
-
ISSN:
-
ZDBID:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
- Neue Suche nach: 44.40 / 44.40$jPharmazie$jPharmazeutika
- Weitere Informationen zu Basisklassifikation
-
Schlagwörter:
-
Klassifikation:
BKL: 44.40 Pharmazie, Pharmazeutika / 44.40$jPharmazie$jPharmazeutika -
Datenquelle:
Inhaltsverzeichnis – Band 35, Ausgabe 5
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 539
-
New doxorubicin nanocarriers based on cyclodextrinsViale, Maurizio / Giglio, Valentina / Monticone, Massimiliano / Maric, Irena / Lentini, Giovanni / Rocco, Mattia / Vecchio, Graziella et al. | 2017
- 545
-
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulationOlbryt, Magdalena / Rusin, Aleksandra / Fokt, Izabela / Habryka, Anna / Tudrej, Patrycja / Student, Sebastian / Sochanik, Aleksander / Zieliński, Rafał / Priebe, Waldemar et al. | 2017
- 556
-
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemiaMori, Masamichi / Kaneko, Naoki / Ueno, Yoko / Yamada, Masaki / Tanaka, Ruriko / Saito, Rika / Shimada, Itsuro / Mori, Kenichi / Kuromitsu, Sadao et al. | 2017
- 566
-
Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1Zhen, Zijun / Yang, Kaibin / Ye, Litong / You, Zhiyao / Chen, Rirong / Liu, Ying et al. | 2017
- 576
-
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsInfante, Jeffrey R. / Cohen, Roger B. / Kim, Kevin B. / Burris, Howard A. / Curt, Gregory / Emeribe, Ugochi / Clemett, Delyth / Tomkinson, Helen K. / LoRusso, Patricia M. et al. | 2017
- 589
-
Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancervan Andel, L. / Fudio, S. / Rosing, H. / Munt, S. / Miguel-Lillo, B. / González, I. / Tibben, M. M. / de Vries, N. / de Vries Schultink, A. H. M. / Schellens, J. H. M. et al. | 2017
- 599
-
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancerCrabb, Simon J. / Birtle, Alison J. / Martin, Karen / Downs, Nichola / Ratcliffe, Ian / Maishman, Tom / Ellis, Mary / Griffiths, Gareth / Thompson, Stuart / Ksiazek, Lidia et al. | 2017
- 608
-
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)Arnold, Susanne M. / Chansky, Kari / Leggas, Markos / Thompson, Michael A. / Villano, John L. / Hamm, John / Sanborn, Rachel E. / Weiss, Glen J. / Chatta, Gurkamal / Baggstrom, Maria Q. et al. | 2017
- 616
-
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumorsMita, Monica / Fu, Siqing / Piha-Paul, Sarina Anne / Janku, Filip / Mita, Alain / Natale, Ronald / Guo, Wei / Zhao, Charles / Kurzrock, Razelle / Naing, Aung et al. | 2017
- 627
-
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersDiamond, Jennifer R. / Goff, Barbara / Forster, Martin D. / Bendell, Johanna C. / Britten, Carolyn D. / Gordon, Michael S. / Gabra, Hani / Waterhouse, David M. / Poole, Mark / Ross Camidge, D. et al. | 2017
- 634
-
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase CAlmhanna, Khaldoun / Wright, David / Mercade, Teresa Macarulla / Van Laethem, Jean-Luc / Gracian, Antonio Cubillo / Guillen-Ponce, Carmen / Faris, Jason / Lopez, Carolina Muriel / Hubner, Richard A. / Bendell, Johanna et al. | 2017
- 642
-
Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancerIgawa, Satoshi / Otani, Sakiko / Ryuge, Shinichiro / Fukui, Tomoya / Nakahara, Yoshiro / Hiyoshi, Yasuhiro / Ishihara, Mikiko / Kusuhara, Seiichiro / Harada, Shinya / Mitsufuji, Hisashi et al. | 2017
- 649
-
Resistance to immunotherapy: clouds in a bright skyMilano, Gérard et al. | 2017
- 655
-
Gankyrin as a potential therapeutic target for cancerWang, Chongchong / Cheng, Li et al. | 2017
- 662
-
Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexedMatama, Goushi / Tokito, Takaaki / Takeoka, Hiroaki / Hiraoka, Yuki / Matsuo, Norikazu / Nakamura, Masayuki / Ishii, Hidenobu / Kinoshita, Takashi / Azuma, Koichi / Yamada, Kazuhiko et al. | 2017
- 665
-
Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidenceAdrianzen Herrera, Diego A. / Fleisig, Sarah B. / Gartrell, Benjamin A. et al. | 2017
- 669
-
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsInfante, Jeffrey R. / Cohen, Roger B. / Kim, Kevin B. / Burris, Howard A. / Curt, Gregory / Emeribe, Ugochi / Clemett, Delyth / Tomkinson, Helen K. / LoRusso, Patricia M. et al. | 2017